GLOFIT: Evaluating Glofitamab + Gemcitabine + Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (H-55651)
Description
Content
GLOFIT: A Phase Ib Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
For more information: https://clinicaltrials.gov/study/NCT06624085
Contact
Phone 1: 713–798–2878
IRB: H-55651
Status:
Active
Created:
